LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Novocure Ltd

Ouvert

SecteurSoins de santé

17.52 -1.46

Résumé

Variation du prix de l'action

24h

Actuel

Min

17.43

Max

18.27

Chiffres clés

By Trading Economics

Revenu

-47M

-71M

Ventes

-295K

174M

BPA

-0.62

Marge bénéficiaire

-40.871

Employés

1,605

EBITDA

-29M

-63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+46.23% upside

Dividendes

By Acuity

Prochains Résultats

23 juil. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

506M

2B

Ouverture précédente

18.98

Clôture précédente

17.52

Sentiment de l'Actualité

By Acuity

50%

50%

146 / 342 Classement par Healthcare

Novocure Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

À Propos Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat